Zydus Lifesciences is set to be in focus after it received tentative approval from the United States Food and Drug Administration for Empagliflozin and Linagliptin combination tablets for type 2 diabetes, alongside final approval for a blood pressure treatment drug. The company also entered into a licensing and commercialisation pact with RK Pharma for a supportive oncology product in the US. Shares ended marginally lower on Thursday as investors assessed the latest regulatory developments.